DrugBank ID:

DB00116

Description:

Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. [DrugBank]

Targets:

C-1-tetrahydrofolate synthase, cytoplasmic (Humans); Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (Humans); Aminomethyltransferase, mitochondrial (Humans); Cytosolic 10-formyltetrahydrofolate dehydrogenase (Humans); Methionine synthase (Humans); Formimidoyltransferase-cyclodeaminase (Humans); Bifunctional purine biosynthesis protein PURH (Humans); Serine hydroxymethyltransferase, cytosolic (Humans); Serine hydroxymethyltransferase, mitochondrial (Humans); Methylenetetrahydrofolate reductase (Humans); Serine hydroxymethyltransferase (Humans); Methionyl-tRNA formyltransferase, mitochondrial (Humans) [DrugBank]

Pharmacodynamics:

Tetrahydrofolate is the main active metabolite of dietary folate. It is vital as a coenzyme in reactions involving transfers of single carbon groups. Tetrahydrofolate has a role in nucleic and amino acid synthesis. As nucleic and amino acid synthesis is affected by a deficiency of tetrahydrofolate, actively dividing and growing cells tend to be the first affected. Tetrahydrofolate is used to treat topical sprue and megaloblastic and macrocytic anemias, hematologic complications resulting from a deficiency in folic acid. [DrugBank]

SMILES:

Nc1nc2c(c(=O)[nH]1)NC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2

2D structures:  

3D structures: